AGA GI Opportunity Fund

The AGA GI Opportunity Fund is a niche venture capital vehicle backed by the American Gastroenterological Association, headquartered in Bethesda, Maryland. Unlike generalist healthcare funds, its mandate is tightly defined around innovation in gastroenterology, including diagnostic devices, therapeutic devices, digital health platforms supporting GI workflows, and adjacent technologies that affect the gastroenterology specialty. Its institutional sponsorship by the AGA gives the fund unusual depth of access to specialist clinicians, society guidelines, and the broader GI research community.

The fund invests at seed and Series A stages, with check sizes typically in the $250,000 to $1M range. Geographic activity is concentrated in the United States, where the AGA’s clinician network is densest, although portfolio companies may pursue international commercialization. Deal types span medical device startups developing novel endoscopic, imaging or diagnostic tools, alongside digital health platforms targeting GI care delivery, patient adherence, and clinical decision support. The fund typically participates as one element of a syndicated early round rather than as a sole lead.

For founders, the AGA GI Opportunity Fund offers a combination of early capital and direct access to a specialty society’s clinical and academic network. Companies most aligned with the fund are those whose product strategy depends on gastroenterologist adoption, society endorsement pathways, or clinical evidence development within GI-specific guidelines. Founders should expect engagement that prioritizes clinical advisory introductions, specialty congress visibility, and KOL alignment. The fund is less suited to broad-spectrum digital health or therapeutic platforms unrelated to GI, and best suited to teams whose commercial path depends on deep penetration of the gastroenterology specialty.